In the head to head SUSTAIN 7 trial, patients taking Ozempic 1mg lost approximately 12.8 pounds compared to 6.2 pounds with Trulicity 1.5mg over 40 weeks
Patients should always inform their GP, practice nurse, and diabetes specialist team about their Ozempic prescription, including the dose and duration of treatment
At Ascension, we see vitamin injections as one part of a much larger picture
3) Glycaemic and metabolic marker panels Retatrutide trials in type 2 diabetes and obesity settings have reported changes in glycaemic markers alongside weight change
Within this population: 8,533 individuals were included in the semaglutide versus other glucose-lowering drug comparison (2,397 vs 6,136) 7,455 individuals were included in the semaglutide versus SGLT2 inhibitor comparison (1,650 vs 3,725) Key findings reduced risk of seizures After statistical adjustment, initiation of semaglutide was associated with a lower risk of epilepsy or seizures compared with both comparator groups: Compared with other glucose-lowering drugs: Hazard ratio: 0.46 95% confidence interval: 0.250.83 P = .010 Compared with SGLT2 inhibitors: Hazard ratio: 0.44 95% confidence interval: 0.220.86 P = .017 These findings suggest a meaningful reduction in relative risk among those initiating semaglutide
Diarrhea : Some people experience loose stools or diarrhea, especially when first using semaglutide
